How we rate providers: Transparent, patient-first scoring →
CareBareRX homepage showing GLP-1 weight loss services

CareBareRX

CareBareRX homepage showing GLP-1 weight loss services
CareBareRX
Our Review
CareBareRX earns a 3.0 out of 5.0 on our weighted scoring system, placing it in the "Use Caution" tier. The availability of both brand-name Ozempic and compounded options is a genuine strength, but the platform's youth, lack of external reviews, low cost transparency, and absence of clinical depth (no labs, no dietitian) mean patients should carefully compare against better-established alternatives. Until CareBareRX builds a verifiable track record, we recommend exploring providers with stronger trust and reputation signals.
Clinical Quality
Support
Patient Protection
Cost & Value
Access
Trust & Transparency
Authenticity
Reputation
Reader Rating0 Votes
What We Like
Both brand-name (Ozempic) and compounded GLP-1 options available
Both oral and subcutaneous delivery formats
Nationwide telehealth coverage
Multi-category platform (weight loss, hair, sexual health)
Pricing starts at $199/month for compounded options
What Could Be Better
No Trustpilot reviews and no BBB listing — zero external reputation
Low cost transparency — difficult to understand full pricing before signup
No lab testing or dietitian access included
Low ongoing support and low trust/compliance transparency
Unknown Certificate of Analysis (CoA) status for compounded medications
Very new platform (founded 2025) with no track record
Wide price range ($199-$705) without clear tier explanations
3
Use Caution
💊
Medications
Compounded, Ozempic
💰
Monthly Cost
$199 – $705

Speed to Start
Moderate

Trustpilot
Not yet rated
✓ Verified Provider
Est. 2025

About CareBareRX

CareBareRX is a lifestyle-focused telehealth platform founded in 2025 that offers treatments across weight loss, hair growth, and sexual health. Their GLP-1 program includes both compounded medications and brand-name Ozempic, delivered through oral and subcutaneous formats — giving patients flexibility in treatment approach.

Monthly pricing ranges from $199 to $705, a wide spread that reflects the gap between compounded and brand-name options. The platform claims high provider quality, but the clinical program lacks the depth of top-tier competitors — no lab testing and no dietitian access are included, and ongoing support is rated low.

The biggest concern with CareBareRX is the near-total absence of external validation. There are no Trustpilot reviews, no BBB listing, and the platform was only founded in 2025. Cost transparency is rated low, which makes it difficult for patients to understand the full financial commitment before signing up.

Trust and compliance transparency is also rated low. For a platform selling compounded injectable medications, the lack of publicly disclosed pharmacy partners and unknown Certificate of Analysis (CoA) status raises questions about sourcing quality. The brand’s multi-category approach (weight loss + hair + sexual health) suggests a generalist model rather than GLP-1-focused clinical expertise.

CareBareRX may appeal to patients looking for a one-stop telehealth platform across multiple health concerns, but the lack of reputation data and clinical depth means patients should proceed with clear expectations and do additional due diligence.

At a Glance

Medications Offered

Compounded, Ozempic

Both

Cost & Insurance

  • Monthly: $199 – $705
  • 6-month estimate: $1200 – $4230
  • Insurance: No
  • Self-pay: Yes

Clinical Features

  • Lab testing: No
  • Dietitian access: No
  • BBB Rating:

Delivery & Access

  • Format: Both (Oral and Subcutaneous)
  • Nationwide telehealth: Yes
  • Speed: Moderate
  • Spanish-speaking providers: Not available

From the Inside

What the CareBareRx Intake Looks Like

We walked through CareBareRx’s full GLP-1 intake ourselves, from the identity-first opening screen through the contraindications multi-select to the treatment-selection page that surfaces both compounded options and brand-name Ozempic. Here’s what an actual prospective patient encounters before being prescribed.

16
Total Screens
~6 min
Time to Complete
5
Distinct Stages

Clinical Rigor
7
/ 10

A transparent contraindications multi-select with Bipolar Disorder and Schizophrenia named explicitly, MTC + MEN2 personal AND family history as separate items, hypoglycemia as a discrete checkbox, modern MASLD/MASH terminology, and free-text allergies and surgeries lists. Knocked down by no validated PHQ, no severity grading on eating disorders, no opiate/alcohol breakdown, no BP/HR range reading, and current-meds Yes/No only.

Friction Level
5
/ 10

Moderate. CareBareRx collects first name, last name, email, and gender on the very first screen — meaningfully more identity-up-front than peer platforms that run the questionnaire anonymously. Approve-first-charge applies at the plan-selection step, but the $80 fee disclosure contradicts itself between the verification stage and the final payment-page attestation.

The 5 Stages

Stage 1
Goal (Identity-First)
Opening screen captures first name, last name, email, and gender. Then weight-loss goal selector (1–20 / 21–50 / over 50 / maintain / none / other), past-initiatives multi-select (exercise, dieting, supplements, intermittent fasting, none), and an age + height + weight + BMI block.
Stage 2
Medication
Two Yes/No questions: currently taking GLP-1 medications, and currently taking any other medications (Rx, OTC, supplements). No follow-up list is captured for either.
Stage 3
Health (Two Multi-Selects)
The “high-risk” contraindications multi-select: Gastroparesis, Pancreatic Cancer, Pancreatitis, T1D / insulin, Hypoglycemia, MTC + family history, Bipolar Disorder, Schizophrenia, MEN-2 + family history, Anorexia or Bulimia, Symptomatic Gallstones / Gallbladder Disease, Active Substance Abuse Disorder. Then a comorbidity multi-select with hypertension, high cholesterol, T2D, OSA, gout, metabolic syndrome, heart disease, stroke, PVD, heart failure, AFib / flutter, tachycardia, ECG abnormality, gallbladder removed, fatty liver (MASLD/MASH), CKD stage 3+. Plus a free-text “List any surgeries” field with N/A fallback.
Stage 4
Allergies
Free-text “List all of your known allergies” field with examples (Penicillin, Pollen, Shellfish, Latex) and a type-N/A fallback for patients with none.
Stage 5
Verification → Treatment → Payment
State of residence, consultation method (Email/Text Message free, Video $80, Phone $80), DOB + phone + attestation. Treatment selection: Compounded Semaglutide from $199, Compounded Tirzepatide from $299, or brand-name Ozempic® from $705. Plan tier — Month-to-Month, 3-month $748, 6-month $1268 “Most Popular,” or 12-month $2218 “Best Value.” Payment with the contradictory $80 fee disclosure.

Clinical Safety Screens Performed

Bipolar Disorder & Schizophrenia — explicit checkboxes (rare)
MTC + MEN2 personal AND family history (separate items)
Hypoglycemia as a discrete checkbox (specific clinical signal)
Cardiac arrhythmia — AFib / flutter, tachycardia, ECG abnormality
Heart Failure as a separate checkbox
Fatty Liver (MASLD / MASH) — modern nomenclature
Free-text allergies list with N/A fallback
Free-text past surgeries with N/A fallback

⚠ What CareBareRx’s Intake Doesn’t Do

The intake doesn’t use a validated PHQ-2 or PHQ-9 depression screen and doesn’t ask about self-harm. Bipolar Disorder and Schizophrenia are listed as contraindications, but there is no separate depression checkbox or severity grading for any mental-health condition. Eating disorders are checkbox items (anorexia or bulimia) rather than a dedicated screen. Substance use is collapsed into a single “Active Substance Abuse Disorder” checkbox — no opiate or alcohol breakdown. There is no actual blood pressure or heart-rate range, only checkbox items. Current medications are captured as a Yes/No only with no follow-up list. There’s no diet or exercise history depth, sex is collected as a binary Male / Female only, and no ID upload or phone OTP is required.

💡 Notable Pricing Inconsistency in the Fee Disclosure

CareBareRx surfaces the $80 telehealth-consultation fee in two different ways during the flow, and the two disclosures contradict each other. At the verification stage, the on-screen note reads: “$80 consultation fee will apply only if your prescription is approved and you choose not to proceed with treatment. The consultation is free if you move forward with purchasing your prescription.” But on the final payment page, the mandatory attestation checkbox reads: “There is an $80 Telehealth consultation fee that will be charged regardless of whether I receive a prescription.” Patients should not assume the conditional disclosure is the binding one — the payment-page attestation is the language they’re consenting to. The plan-selection page does say “Payment will not be processed until approval is made,” so the medication itself is approve-first-charge, but the consultation-fee mechanic is unclear from the visible flow alone.

Source: GLP-1.Reviews editorial walkthrough on April 30, 2026. We completed every screen of the CareBareRx weight-loss intake using a representative GLP-1 candidate persona and stopped before submitting any payment information.

Visit CareBareRx →

Opens carebarerx.com in a new tab.

Visit CareBareRX →

Start your GLP-1 weight loss journey with CareBareRX today

Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.

Editorial Independence: GLP-1.Reviews maintains full editorial independence. Our scores are based on verified data and standardized criteria.

CareBareRX
3.0 / 5.0
Mixed Signals

Let's Review Widget